Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-low-dose versus standard-low-dose triple combination therapy for hypertension
ACTRN12617001533381Phase 4Not yet recruiting
- Sponsor
- George Medicines
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of telmisartan, amlodipine, indapamide, losartan and hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by George Medicines. Primary endpoint: Short-term safety of ultra-low-dose versus standard-low-dose triple combination therapy. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
telmisartanamlodipineindapamidelosartanhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ACTRN12617001533381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001533381.